Sequential use of sorafenib and regorafenib in hepatocellular cancer recurrence after liver transplantation: treatment strategies and outcomes
| dc.contributor.author | Özbay, Mehmet Fatih | |
| dc.contributor.author | Harputluoğlu, Hakan | |
| dc.contributor.author | Karaca, Mustafa | |
| dc.contributor.author | Tekin, Ömer | |
| dc.contributor.author | Şendur, Mehmet Ali Nahit | |
| dc.contributor.author | Bilici, Ahmet | |
| dc.contributor.author | Tatlı, Ali Murat | |
| dc.date.accessioned | 2025-11-21T11:28:19Z | |
| dc.date.available | 2025-11-21T11:28:19Z | |
| dc.date.issued | 2024 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
| dc.description.abstract | Background and Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation. We focused on survival outcomes, treatment responses, and the management of side effects in this patient group. Methods: We conducted a retrospective analysis of 73 patients who experienced HCC recurrence post-liver transplantation between 2012 and 2022 across 11 oncology centers in Turkey. Patients were categorized according to Child–Pugh classification and treated with sorafenib as first-line therapy and Regorafenib in case of progression. Survival rates were analyzed using the Kaplan–Meier method, and risk factors were evaluated using Cox regression analysis. Results: Of the 73 patients included in the study, 62 were male (84.9%), and 11 were female (15.1%), with a mean age of 61.5 ± 10.9 years. All patients received sorafenib as first-line treatment. Among patients who experienced progression with sorafenib or discontinued treatment due to toxicity, 45.2% (n = 33) continued treatment with regorafenib. The median progression-free survival (PFS1) time with sorafenib was 5.6 months, and the one-year survival rate was 24.3%. The median progression-free survival (PFS2) time with regorafenib, which was administered as second-line treatment, was also calculated as 5.9 months. Overall survival (OS) duration was determined as 35.9 months. The most common side effects associated with both drugs included fatigue, hand and foot syndrome, and hypertension. Significantly better survival outcomes were shown in the Child–Pugh A group compared to other patients. Conclusions: These results suggest that Sorafenib and Regorafenib treatments offer a survival advantage in patients with relapsed HCC post-transplantation. However, individualized treatment strategies and close follow-up are crucial for optimizing outcomes. Further studies are needed to refine therapeutic protocols and enhance the care of this specific patient group. | |
| dc.identifier.citation | Özbay, M., Harputluoğlu, H., Karaca, M., Tekin, Ö., Şendur, M. A. N., Bilici, A. ... Tatlı, A. M. (2024). Sequential use of sorafenib and regorafenib in hepatocellular cancer recurrence after liver transplantation: treatment strategies and outcomes. Cancers, 16(22). http://dx.doi.org/10.3390/cancers16223880 | |
| dc.identifier.doi | 10.3390/cancers16223880 | |
| dc.identifier.issn | 2072-6694 | |
| dc.identifier.issue | 22 | |
| dc.identifier.pmid | 39594835 | |
| dc.identifier.scopus | 2-s2.0-85211074455 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | http://dx.doi.org/10.3390/cancers16223880 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/13230 | |
| dc.identifier.volume | 16 | |
| dc.identifier.wos | WOS:001364175500001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Bilici, Ahmet | |
| dc.institutionauthorid | 0000-0002-0443-6966 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Cancers | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights | Attribution 4.0 International | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Hepatocellular Carcinoma (HCC) | |
| dc.subject | Liver Transplantation | |
| dc.subject | Post-Transplant Recurrence | |
| dc.subject | Regorafenib | |
| dc.subject | Sorafenib | |
| dc.title | Sequential use of sorafenib and regorafenib in hepatocellular cancer recurrence after liver transplantation: treatment strategies and outcomes | |
| dc.type | Article |
